NUCEIVA (PrabotulinumtoxinA)
Botulinum toxin type A – neurotoxin for temporary improvement of moderate to severe glabellar lines
Quick Facts About NUCEIVA
Key Takeaways About NUCEIVA
- Prescription botulinum toxin: NUCEIVA is a neurotoxin that must be administered by a trained healthcare professional via intramuscular injection
- Approved for frown lines: Currently approved for moderate to severe glabellar lines (frown lines) in adults; 20 units per treatment session
- Not interchangeable: NUCEIVA units cannot be compared to or converted into units of other botulinum toxin products like BOTOX or Dysport
- Results within days: Effects typically appear within 2–3 days, peak at 4 weeks, and last approximately 3 months
- Important safety warning: Effects may spread from the injection area causing difficulty swallowing and breathing, which can be life-threatening in rare cases
What Is NUCEIVA and What Is It Used For?
NUCEIVA (prabotulinumtoxinA-xvfs) is a prescription botulinum toxin type A product that temporarily reduces muscle activity in the face to improve the appearance of moderate to severe frown lines (glabellar lines) between the eyebrows in adults.
NUCEIVA belongs to a class of medications known as neuromuscular blocking agents. It contains botulinum toxin type A, a purified neurotoxin complex produced from the bacterium Clostridium botulinum. The product is manufactured using a proprietary vacuum-drying process (as opposed to the freeze-drying method used by some other botulinum toxin products), and is marketed under the brand name Jeuveau in the United States.
The medication was first approved by the U.S. Food and Drug Administration (FDA) in February 2019 and received European marketing authorization from the European Commission in September 2019. It is the first botulinum toxin product developed exclusively for aesthetic use, specifically targeting the cosmetic treatment of glabellar lines.
NUCEIVA works through a well-characterized mechanism of action. When injected into the target muscles, the toxin binds to receptors at motor nerve terminals and is taken up into the nerve ending through a process called endocytosis. Once inside, it cleaves a protein called SNAP-25 (Synaptosomal-associated protein 25), which is essential for the release of the neurotransmitter acetylcholine at the neuromuscular junction. By blocking acetylcholine release, NUCEIVA produces localized, partial chemical denervation of the treated muscles, resulting in reduced muscle activity and a smoother appearance of the overlying skin.
The effects of the treatment are temporary because the body gradually forms new nerve connections to the muscles through a process called axonal sprouting. This reinnervation gradually reverses the chemical denervation, which is why treatments typically need to be repeated every three months to maintain results.
NUCEIVA is approved for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. In the European Union, the indication specifies adults below 65 years of age when the severity of these lines has an important psychological impact on the patient.
What Should You Know Before Receiving NUCEIVA?
Before receiving NUCEIVA, your healthcare provider needs to know about your complete medical history, including any neuromuscular disorders, allergies, current medications, and whether you are pregnant or breastfeeding. Several conditions and medications can increase the risk of serious side effects.
Contraindications
NUCEIVA must not be used in certain situations. Your healthcare provider should not administer this medication if any of the following apply to you:
- Hypersensitivity: Known allergy to botulinum toxin type A or any of the product's ingredients (human serum albumin, sodium chloride)
- Active infection: Infection or inflammation at the planned injection sites on the face
- Neuromuscular disorders: Generalized muscle disorders such as myasthenia gravis or Lambert-Eaton syndrome (these conditions significantly increase the risk of severe weakness, swallowing difficulties, and respiratory compromise)
Patients with these conditions were excluded from the clinical trials that evaluated NUCEIVA, meaning there is no safety data available for these populations. The presence of peripheral motor neuropathies or amyotrophic lateral sclerosis (ALS) also places patients at significantly increased risk and NUCEIVA should generally be avoided in these individuals.
Warnings and Precautions
The effects of all botulinum toxin products, including NUCEIVA, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening and there have been reports of death. The risk is greatest in children treated for spasticity (an unapproved use for NUCEIVA), but symptoms can also occur in adults treated for approved indications.
Beyond the boxed warning, there are several additional safety considerations that patients and healthcare providers should be aware of:
- Non-interchangeability: The potency units of NUCEIVA are specific to its proprietary bioassay method. One unit of NUCEIVA is not equivalent to one unit of any other botulinum toxin product (such as onabotulinumtoxinA/BOTOX, abobotulinumtoxinA/Dysport, or incobotulinumtoxinA/Xeomin). Dose conversions between products should never be attempted.
- Cardiovascular risks: Reports of cardiac arrhythmia and myocardial infarction, including fatalities, have been associated with botulinum toxin use, some in patients with pre-existing cardiovascular disease.
- Ocular effects: Dry eye has been reported following treatment of glabellar lines, likely related to reduced tear production, diminished blinking, or corneal exposure. Patients with a history of reduced corneal sensation or prior eye surgery should exercise particular caution.
- Bleeding risk: Patients taking anticoagulants or those with bleeding disorders may experience increased bruising and hematoma formation at the injection sites.
- Antibody formation: Some patients may develop neutralizing antibodies to botulinum toxin over time, potentially reducing the effectiveness of future treatments. In clinical trials, this occurred in fewer than 0.2% of patients.
- Human albumin content: NUCEIVA contains human serum albumin as a stabilizer. While the theoretical risk of viral transmission through albumin-containing products is considered extremely remote, no documented cases have ever been reported.
Pregnancy and Breastfeeding
The use of NUCEIVA during pregnancy has not been adequately studied in humans. Animal reproductive studies in pregnant rats at doses up to 12 times the maximum recommended human dose did not reveal adverse fetal effects during organogenesis; however, the relevance of animal studies to human pregnancy is limited. Both the FDA and EMA recommend that NUCEIVA should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus, and the European label specifically states it is not recommended during pregnancy.
It is unknown whether prabotulinumtoxinA-xvfs passes into breast milk or what effects it may have on a breastfed infant. The EMA recommends that NUCEIVA should not be used during breastfeeding. Healthcare providers should weigh the developmental benefits of breastfeeding against the potential risks when making treatment decisions.
The effects of NUCEIVA on human fertility have not been established. Safety and effectiveness have not been studied in children or adolescents under 18 years of age, and the product should not be used in this population.
How Does NUCEIVA Interact with Other Drugs?
NUCEIVA can interact with several types of medications that affect neuromuscular function. Aminoglycosides, neuromuscular blocking agents, and other botulinum toxin products can enhance the effects of NUCEIVA and increase the risk of excessive muscle weakness.
No formal drug interaction studies have been conducted with NUCEIVA. However, based on the pharmacological properties of botulinum toxin type A and clinical experience with the broader class of botulinum toxin products, several clinically important interactions have been identified. Patients should inform their healthcare provider of all medications they are currently taking, including prescription and over-the-counter drugs, supplements, and herbal products.
| Drug / Drug Class | Type | Clinical Consequence | Recommendation |
|---|---|---|---|
| Aminoglycosides (gentamicin, tobramycin, neomycin, amikacin, streptomycin) | Major | Potentiate neuromuscular blockade; increased risk of excessive weakness | Close monitoring required; avoid concurrent use if possible |
| Neuromuscular blocking agents (vecuronium, rocuronium, succinylcholine) | Major | Additive neuromuscular blockade; may cause severe, prolonged muscle paralysis | Avoid concurrent use; if anesthesia required, inform anesthetist |
| Other botulinum toxin products (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA) | Major | Additive neurotoxin burden; increased risk of toxin spread and systemic effects | Do not use concurrently; allow adequate washout period |
| Anticholinergic drugs (atropine, oxybutynin, scopolamine) | Moderate | May potentiate systemic anticholinergic effects | Monitor for increased anticholinergic side effects |
| Muscle relaxants (baclofen, tizanidine, cyclobenzaprine) | Moderate | Additive muscle-weakening effects; potentiation of local effect | Use with caution; monitor for excessive weakness |
| Spectinomycin | Moderate | May potentiate neuromuscular blocking effects similar to aminoglycosides | Monitor closely if concurrent use is necessary |
| Anticoagulants / Antiplatelets (warfarin, aspirin, clopidogrel, heparin) | Minor | Increased bruising and hematoma at injection sites (not a pharmacodynamic interaction) | Inform provider; apply gentle pressure after injection |
Patients who are currently receiving any of the medications listed above should discuss their treatment plan with their healthcare provider before receiving NUCEIVA. In particular, patients receiving aminoglycosides or other drugs that interfere with neuromuscular transmission should be observed closely during and after treatment, as the combined effects can increase the risk of generalized muscle weakness and respiratory difficulties.
What Is the Correct Dosage of NUCEIVA?
The recommended dose of NUCEIVA for glabellar lines is 20 Units (0.5 mL after reconstitution), administered as five intramuscular injections of 4 Units each into the corrugator and procerus muscles. Treatment should be performed only by a qualified healthcare professional.
NUCEIVA is supplied as a sterile, vacuum-dried powder in a single-dose vial containing 100 Units. Before use, the powder must be reconstituted by the healthcare provider with 2.5 mL of sterile, preservative-free 0.9% sodium chloride (normal saline), yielding a concentration of 4 Units per 0.1 mL. The solution should be gently mixed without vigorous shaking and must appear clear, colorless, and free of particulate matter before use.
Adults (Under 65 Years in EU)
Glabellar Lines – Standard Dosing Protocol
The recommended total dose is 20 Units (0.5 mL), divided into 5 equal intramuscular injections of 4 Units (0.1 mL) each:
| Injection Site | Dose | Volume |
|---|---|---|
| Left inferomedial corrugator muscle | 4 Units | 0.1 mL |
| Left superior middle corrugator muscle | 4 Units | 0.1 mL |
| Right inferomedial corrugator muscle | 4 Units | 0.1 mL |
| Right superior middle corrugator muscle | 4 Units | 0.1 mL |
| Midline procerus muscle | 4 Units | 0.1 mL |
The injection should be performed using a sterile needle (typically a 30-gauge needle). The healthcare provider should use their non-dominant hand to stabilize the injection area and ensure that the needle is placed accurately within the target muscle. It is critical to avoid injecting near the levator palpebrae superioris muscle to minimize the risk of eyelid drooping (ptosis), and injection into blood vessels must be avoided.
Children and Adolescents
The safety and effectiveness of NUCEIVA have not been established in patients under 18 years of age. This product should not be used in children or adolescents. The boxed warning specifically notes that the risk of distant spread of toxin effects is greatest in children.
Elderly Patients
The European label restricts the approved use of NUCEIVA to adults below 65 years of age. In the United States, 68 subjects aged 65 years and older were included in clinical trials, and no overall differences in safety or efficacy were observed compared to younger patients. However, the numbers were insufficient for definitive conclusions. Due to the natural age-related changes in muscle mass and skin, healthcare providers should use clinical judgment when treating older patients.
Missed Treatment
Since NUCEIVA is administered by a healthcare professional in a clinical setting, there is no concern about missing a dose in the traditional sense. If a patient misses a scheduled treatment appointment, they should reschedule as soon as convenient. Treatment intervals should generally be no more frequent than every 3 months. There are no known adverse consequences of extending the time between treatments beyond 3 months – the cosmetic effects will simply gradually wear off as the neuromuscular function recovers.
Overdose
Excessive doses of botulinum toxin type A may produce neuromuscular weakness with a range of symptoms. Signs of overdose may not appear immediately following injection and can develop over several days to weeks. Symptoms may include general muscle weakness, ptosis (drooping eyelids), diplopia (double vision), difficulty swallowing (dysphagia), difficulty speaking (dysphonia), and respiratory difficulties.
In the event of suspected overdose or if signs of distant spread of toxin effect develop, the patient should be monitored in a medical facility. Supportive care, including respiratory support if needed, should be provided. An antitoxin may be available through public health authorities, but its effectiveness after symptom onset is uncertain. Each vial contains 100 Units, but only 20 Units are used per treatment session for glabellar lines. Unused product must be discarded.
What Are the Side Effects of NUCEIVA?
The most commonly reported side effects of NUCEIVA include headache (9–12%), injection site reactions (pain, bruising, swelling), eyelid drooping (1–2%), and upper respiratory tract infection (3%). Most side effects are mild to moderate and resolve without treatment.
The safety profile of NUCEIVA has been evaluated in Phase III clinical trials involving 492 patients treated with NUCEIVA and 162 patients receiving placebo. The majority of treatment-emergent adverse events were mild to moderate in severity. Below is a comprehensive breakdown of side effects organized by frequency, based on data from clinical trials, the European Summary of Product Characteristics (SmPC), and post-marketing surveillance reports.
Common Side Effects
- Headache (9–12%)
- Upper respiratory tract infection (3%)
- Eyelid drooping / blepharoptosis (1–2%)
- Injection site pain
- Injection site bruising (ecchymosis)
- Injection site swelling (edema)
- Injection site redness (erythema)
- Injection site tenderness
- Elevated white blood cell count (1%)
Uncommon Side Effects
- Dizziness
- Migraine
- Muscle tone disorder
- Pruritus (itching)
- Blurred vision
- Eyebrow drooping / ptosis (0.4%)
- Double vision / diplopia (0.4%)
Rare Side Effects
- Depression
- Abnormal skin sensations (dysaesthesia)
- Dry eye / reduced tear production
- Flushing
- Nosebleed (epistaxis)
- Muscle atrophy at injection site
- Vasovagal syncope (fainting)
- Facial weakness in unintended muscles
- Flu-like symptoms (malaise, fever)
Very Rare / Post-Marketing Reports
- Severe allergic reactions (anaphylaxis, angioedema, urticaria)
- Distant spread of toxin: generalized weakness, difficulty swallowing, aspiration pneumonia, respiratory failure
- Serum sickness
- Soft tissue edema distant from injection site
- Cardiac arrhythmia, myocardial infarction (in patients with pre-existing cardiovascular disease)
In clinical trials, the adverse events of particular interest that were directly attributable to NUCEIVA treatment included eyelid ptosis (1.6%), eyebrow ptosis (0.4%), blurred vision (0.4%), and diplopia (0.4%). All of these events resolved on their own without intervention. Headache was the most commonly reported adverse event, but occurred at similar rates in both the NUCEIVA group (12%) and the placebo group (13%), suggesting it may be partially related to the injection procedure rather than the medication itself.
Contact your healthcare provider or seek emergency medical care immediately if you experience difficulty swallowing, speaking, or breathing after receiving NUCEIVA. Also seek immediate care for signs of a severe allergic reaction, including hives, swelling of the face, lips, tongue or throat, and difficulty breathing. These are rare but potentially serious complications.
Immunogenicity is an additional consideration with long-term use. In clinical trials involving 1,414 subjects, 2 patients had pre-existing antibodies and 2 patients developed treatment-emergent neutralizing antibodies (fewer than 0.2%). The development of such antibodies can potentially reduce the effectiveness of NUCEIVA over time, although this appears to occur very rarely.
How Should You Store NUCEIVA?
Unopened NUCEIVA vials should be stored in a refrigerator at 2–8°C (36–46°F) in the original carton to protect from light. Do not freeze. After reconstitution, use within 24 hours (FDA) or up to 72 hours if kept refrigerated (EU label).
Proper storage of NUCEIVA is essential to maintain the potency and safety of the product. Since NUCEIVA is administered exclusively in healthcare settings, storage is typically the responsibility of the clinic or healthcare facility rather than the patient. However, understanding the storage requirements can help patients ask informed questions about how their treatment product is being handled.
Unopened Vials
- Store in a refrigerator at 2–8°C (36–46°F)
- Keep in the original carton to protect from light
- Do not freeze
- Shelf life is 30 months from the date of manufacture when stored correctly
- Do not use after the expiry date printed on the carton and vial label
After Reconstitution
- Store reconstituted solution in the refrigerator at 2–8°C, protected from light
- Use within 24 hours of reconstitution (FDA recommendation)
- The EU label permits use within up to 72 hours if stored at 2–8°C
- Do not freeze the reconstituted solution
- Contains no preservative – discard any unused portion after the treatment session
- Use one vial per patient per session only (single-dose vial)
From a chemical and physical perspective, in-use stability has been demonstrated for up to 72 hours at 2–8°C when protected from light. However, from a microbiological standpoint, since the product contains no preservative, it should be used as soon as possible after reconstitution. Any unused product or waste material should be disposed of in accordance with local healthcare waste regulations.
What Does NUCEIVA Contain?
Each NUCEIVA vial contains 100 Units of botulinum toxin type A (prabotulinumtoxinA-xvfs) as the active ingredient, with human serum albumin (0.5 mg) and sodium chloride (0.9 mg) as inactive ingredients. The product is preservative-free.
NUCEIVA has a simple and well-characterized formulation. The product is presented as a sterile, vacuum-dried powder in a Type I glass vial sealed with a chlorobutyl rubber stopper and aluminum cap. Unlike many other botulinum toxin products that use freeze-drying (lyophilization), NUCEIVA uses a vacuum-drying process during manufacture, which is a distinguishing feature of this product.
| Component | Amount | Function |
|---|---|---|
| Botulinum toxin type A (prabotulinumtoxinA-xvfs) | 100 Units | Active ingredient – neurotoxin complex from Clostridium botulinum |
| Human serum albumin (HSA) | 0.5 mg | Stabilizer – protects the toxin during storage |
| Sodium chloride | 0.9 mg | Excipient – tonicity agent |
The active substance, botulinum toxin type A neurotoxin complex, is a high-molecular-weight complex (approximately 900 kDa) produced by fermentation of Clostridium botulinum. The complex consists of the neurotoxin itself along with associated non-toxic proteins (hemagglutinins and non-hemagglutinin non-toxic components) that stabilize the neurotoxin.
Human serum albumin is included as a stabilizer to prevent the toxin from adhering to the glass vial walls and to maintain the biological activity of the product during storage. As with all albumin-containing biological products, there is an extremely remote theoretical risk of viral disease transmission, although no such cases have ever been reported with any albumin-containing botulinum toxin product.
NUCEIVA must not be mixed with any other medicinal products, as no compatibility data exist for co-formulation. For reconstitution, only sterile, preservative-free 0.9% sodium chloride injection should be used.
Frequently Asked Questions About NUCEIVA
NUCEIVA (prabotulinumtoxinA-xvfs) is a prescription botulinum toxin type A product approved for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows) in adults. It works by blocking nerve signals to the muscles responsible for frown lines, temporarily reducing muscle activity and smoothing the overlying skin. It is administered by a healthcare professional as a series of five small injections totaling 20 Units per treatment session.
NUCEIVA and BOTOX are both botulinum toxin type A products, but they are manufactured by different companies using different processes. NUCEIVA uses a vacuum-drying process while BOTOX uses freeze-drying. The potency units of each product are determined by proprietary bioassay methods and are not interchangeable – 1 unit of NUCEIVA is not equivalent to 1 unit of BOTOX. NUCEIVA is currently approved only for glabellar lines (frown lines), while BOTOX has additional approved indications including chronic migraine, cervical dystonia, and hyperhidrosis.
NUCEIVA typically produces visible effects within 2–3 days of injection, with peak effect occurring at approximately 4 weeks. The results generally last about 3 months (12 weeks), after which treatment can be repeated. Retreatment should occur no more frequently than every 3 months. Individual results may vary depending on factors such as muscle mass, the severity of the frown lines, and individual response to the medication.
The most commonly reported side effects include headache (9–12%), injection site reactions (pain, bruising, swelling, and redness), eyelid drooping (ptosis, 1–2%), and upper respiratory tract infection (3%). Most side effects are mild to moderate in severity and resolve on their own without treatment. Serious side effects such as difficulty swallowing or breathing from distant toxin spread are rare but have been reported with botulinum toxin products in general.
In rare cases, the effects of NUCEIVA may spread from the injection area to other parts of the body, causing symptoms such as generalized muscle weakness, difficulty swallowing, speech difficulties, or breathing problems. This is highlighted in the prescribing information as a boxed warning. These effects can occur hours to weeks after injection. If you experience any of these symptoms after treatment, seek emergency medical attention immediately. The risk is considered low when the product is used at approved doses for approved indications by trained healthcare professionals.
NUCEIVA should not be used in people with a known allergy to botulinum toxin type A or any of the product's ingredients (human serum albumin, sodium chloride), those with an active skin infection or inflammation at the planned injection sites, or patients with generalized neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome. It has not been studied in children or adolescents under 18 years of age. In the European Union, it is approved for use in adults under 65 years of age only. Pregnant or breastfeeding women should generally avoid this treatment.
References
This article is based on the following peer-reviewed sources, regulatory documents, and international medical guidelines. All medical claims have evidence level 1A, the highest quality of evidence.
- U.S. Food and Drug Administration (FDA). JEUVEAU (prabotulinumtoxinA-xvfs) Prescribing Information. DailyMed, National Library of Medicine. February 2019 (revised 2023).
- European Medicines Agency (EMA). NUCEIVA – Summary of Product Characteristics (SmPC). European Public Assessment Report (EPAR). September 2019.
- Health Canada. NUCEIVA Product Monograph. Drug Product Database. 2019.
- Carruthers J, et al. “Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines: Results of Two Phase III, Randomized, Double-Blind, Placebo-Controlled Trials.” Dermatologic Surgery. 2020;46(1):30–39.
- Solish N, et al. “Long-term Safety and Efficacy of PrabotulinumtoxinA for Glabellar Lines: An Open-Label Extension Study.” Aesthetic Surgery Journal. 2021;41(6):NP723–NP733.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023.
- British National Formulary (BNF). Botulinum toxin type A – Monograph. National Institute for Health and Care Excellence (NICE). 2024.
- Medicines and Healthcare products Regulatory Agency (MHRA). NUCEIVA – Electronic Medicines Compendium (EMC) SmPC. 2024.
About This Article
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians and pharmacists with expertise in clinical pharmacology, dermatology, and aesthetic medicine. All content follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, and FDA.
iMedic Medical Editorial Team – Specialists in Clinical Pharmacology
iMedic Medical Review Board – Independent expert panel following international guidelines
Level 1A – Based on systematic reviews, randomized controlled trials, and regulatory data
None. iMedic receives no pharmaceutical company funding or sponsorship